Nuocheng Jinhua: Directors and senior executives plan to reduce their holdings in the company by no more than 0.018% of the shares.

Announcement of Lianhua Health: Executive Director, Chairman of the Board, and CEO Jisong Cui intends to reduce his holdings of no more than 206,200 A-shares through centralized bidding from July 16, 2026 to September 30, 2026; Executive Director and Senior Vice President of Hematology Research Renbin Zhao intends to reduce his holdings of no more than 50,000 A-shares; Chief Technical Officer Xiangyang Chen intends to reduce his holdings of no more than 62,500 A-shares. The reasons for reducing holdings are personal financial needs, and the total reduction ratio does not exceed 0.018%.